• Chris H Takimoto.
• Department of Medicine/Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, MSC 7884, San Antonio, TX 78229, USA. takimoto@uthscsa.edu
• Cancer Chemother. Pharmacol. 2003 Jul 1; 52 Suppl 1: S29-33.

AbstractAnticancer drug discovery and development is a rapidly evolving field. Recent advances in molecular oncology and the effort to completely sequence the human genome has led to an explosion in our understanding of the mechanisms involved in the transformation and growth of malignant cells. This in turn has led to major changes in our approach to traditional drug discovery and development. A dynamic example of how genomics is affecting cancer developmental therapeutics is provided by the ongoing changes being implemented in the anticancer drug development program run by the US National Cancer Institute (NCI). This review summarizes the history of drug screening and development efforts at the NCI over the past five decades from its inception up to its current state emphasizing molecularly targeted therapies. These changes have not only had an impact on drug discovery, but they are also providing new paradigms for the design and conduct of preclinical and early clinical trials.

13 keywords...

hide…